Adalimumab – official price, limit, real price (data from NHF – DGL) per 1 mg

2 of brands of adalimumab  (Humira and Imraldi) are reimbursement in Poland under 5 drug programmes. Since the start of reimbursement in 2012 to 2018, the funding limit for 1 mg of adalimumab stayed at similiar level (markdown of 2%), while real price for 1 mg decreased by 20%.

Launch of Imraldi to reimbursement list reduced the funding limit for 1 mg of adalimumab by half (52%) and should generate significant savings of 48,6 mln PLN for the NHF  – total annual sales of adalimumab in previous years amounted to almost 3 million mg and cost nearly 120 million PLN.

 2012201320142015201620172018
(10 msc)
Reimbursement
value
29 958 166 zł79 185 890 zł96 688 891 zł115 357 819 zł110 665 686 zł119 462 701 zł108 540 865 zł
Sales of mg687 5211 530 0571 872 2542 238 3892 561 7222 872 5822 613 704